E
TEVA icon

Ergoteles’s Teva Pharmaceuticals TEVA Stock Holding History

Ergoteles’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-49,814
Closed -$375K – 758
2023
Q2 		$375K Sell
49,814
-27,850
-36% -$226K 0.02% 714
2023
Q1 		$687K Buy
+77,664
New +$768K 0.03% 628
2021
Q3 		– Sell
-201,589
Closed -$2M – 1654
2021
Q2 		$2M Buy
201,589
+52,362
+35% +$554K 0.05% 364
2021
Q1 		$1.72M Buy
+149,227
New +$1.71M 0.05% 301

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Ergoteles's TEVA Position: Q3 2023 in Review

Ergoteles sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 49,814 shares — an estimated $375K sold.

Ergoteles first reported a position in TEVA in Q1 2021 and held it in 4 quarters. The position peaked at $2M in Q2 2021. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Ergoteles reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 49,814 Teva Pharmaceuticals shares in Q3 2023, an estimated $375K.
  • Ergoteles first reported a position in Teva Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • Ergoteles's Teva Pharmaceuticals position peaked at $2M in Q2 2021.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.